Autres langues Sensorion

Actions

ALSEN

FR0012596468

Recherche biotechnologique et médicale

Marché Fermé - Euronext Paris 17:55:00 02/09/2026			Varia. 5j.	Varia. 1 janv.
0,2570 ^EUR	-3,38%		-5,86%	-23,74%

29/07	Sensorion annonce un regroupement d'actions (50 contre 1)
19/06	Small caps - Les derniers choix des stars de la gestion

Autres langues

29/07	Sensorion Announces a Reverse Share Split of its Shares
10/06	Sensorion Achieves Key Regulatory Milestones for Sens-601 for Gjb2-Related Hearing Loss and Selects Program as Lead Gene Therapy Candidate
10/06	Sensorion Applies for Clinical Trial in Canada, France for SENS-601
10/06	Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate
18/05	French Biotech Company Sensorion Names New CEO
18/05	Sensorion : Inside Information / Other news releases
18/05	Sensorion Appoints Fred Chereau as Chief Executive Officer
18/05	Sensorion SA Announces Chief Executive Officer Changes
18/05	Sensorion SA Announces Resignation of Géraldine Honnet as Chief Medical Officer
13/05	Sensorion : Inside Information / Other news releases
13/05	Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions
05/05	Sensorion Announces its Participation in the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
01/05	Certain Ordinary Shares of Sensorion SA are subject to a Lock-Up Agreement Ending on 1-MAY-2026.
22/04	Sensorion Provides Preliminary Documents for the Combined Shareholders General Meeting of May 11, 2026
21/04	Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 11, 2026
23/03	Sensorion Reports Six-Month Update from the Audiogene Phase 1/2 Trial of SENS-501 and Advances GJB2-GT (SENS-601) Toward First-In-Human Clinical Development
23/03	Sensorion : Inside Information / Other news releases
23/03	Sensorion Reports Six-Month Update from the Audiogene Phase 1/2 Trial of SENS-501 and Advances GJB2-GT (SENS-601) Toward First-in-Human Clinical Development
18/03	Sensorion : Inside Information / News release on accounts, results
18/03	Sensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual Report
18/03	Sensorion SA Reports Earnings Results for the Full Year Ended December 31, 2025
17/02	Sensorion Announces CEO Transition
17/02	Sensorion Sa Announces Stepping Down of Nawal Ouzren as Director on the Board
17/02	Sensorion says CEO Nawal Ouzren to step down
17/02	Sensorion's CEO Quits; Chairman Named Interim CEO